Deniz

Deniz Therapeutics is a biotechnology company focused on developing transformative therapies for neurodegenerative diseases, with a primary emphasis on tauopathies and synucleinopathies. The company leverages a proprietary platform to identify and develop small molecules and gene therapies that target the underlying mechanisms of protein aggregation in the brain. Their lead programs are designed to address high unmet needs in conditions such as Alzheimer's disease, Parkinson's disease, and Progressive Supranuclear Palsy. By focusing on the clearance and prevention of toxic protein species, Deniz Therapeutics aims to slow or halt disease progression rather than just managing symptoms. The company is led by a team of experts in neuroscience and drug development and is currently in the pre-clinical stage of its pipeline development.